title: CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study.
abstract: BACKGROUND
  T cells play an important part in Crohn's disease. Immunomodulating therapies that target T cell activation may have clinical effects in Crohn's disease.
  
  
  OBJECTIVE
  To investigate the toxicity and potential efficacy of anti-CD4 monoclonal antibody therapy in patients with Crohn's disease.
  
  
  METHODS
  A dose escalating pilot study was conducted in three groups of four patients with intractable Crohn's disease, refractory to steroids. They received 70, 210, or 700 mg of cM-T412, a depleting anti-CD4 monoclonal antibody (mAb).
  
  
  RESULTS
  The mean reduction in Crohn's disease activity index (CDAI) was respectively 25%, 24%, and 36% at four weeks, and 24% and 52% at 10 weeks in the 210 mg and 700 mg groups. There was only a minor effect on endoscopically evaluated disease activity. Side effects were mild to moderate fever with chills and headache. No signs of opportunistic infection were seen. There was a sustained decrease in CD4 count which lasted at least four weeks in the 70 mg group (76.3 (SD 40.6)% of the baseline value), and 10 weeks in both the 210 mg group (80.8 (SD 60.9)%) and the 700 mg group (24.8 (SD 15.4)%). The primary and secondary humoral immune response was not influenced by anti-CD4 mAb treatment.
  
  
  CONCLUSIONS
  This study shows the moderate potential efficacy of treatment of patients with Crohn's disease using a depleting chimeric monoclonal anti-CD4 antibody.
authors.affiliation: Department of Gastroenterology, Academic Medical Centre, Amsterdam, Netherlands.
authors.forename: A
authors.initials: A
authors.lastname: Stronkhorst
authors.forename: S
authors.initials: S
authors.lastname: Radema
authors.forename: S L
authors.initials: SL
authors.lastname: Yong
authors.forename: H
authors.initials: H
authors.lastname: Bijl
authors.forename: I J
authors.initials: IJ
authors.lastname: ten Berge
authors.forename: G N
authors.initials: GN
authors.lastname: Tytgat
authors.forename: S J
authors.initials: SJ
authors.lastname: van Deventer
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D000917:Antibody Formation; D015704:CD4 Antigens / Q000276:immunology*; D003113:Colonoscopy; D003424:Crohn Disease / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016130:Immunophenotyping; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D018124:Receptors, Tumor Necrosis Factor / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha